An intellectual insight on workplace diversity and inclusiveness.

1. PFIZER Inc.
Technology Initiatives
August 26, 2019
1

2. 2
Business Description
Business Overview
Pfizer Inc. is a research-based, global biopharmaceutical company.
The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines.
The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Innovative Health focuses on developing and commercializing medicines and vaccines that improve patients' lives. Innovative Health therapeutic areas
include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases. Essential Health includes legacy brands, branded generics,
generic sterile injectable products, biosimilars and infusion systems. Essential Health also includes a research and development (R&D) organization as well
as its contract manufacturing business.
The company was incorporated in the state of New York in 1842 and sold its product in over 125 countries and employs ~92400 people.
Head Office
235 East 42nd Street New York
New York, 10017
United States
+212-733-2323
Lidia Fonseca
Executive Vice President, Chief Digital
and Technology Officer

3. 3
Business Segments
Essential Health (EH) – Performance
EH segment reported revenue of US$20,221.0 million for FY2018, which
decreased 4.3% YoY, and recorded negative growth of 7.5% during 2016-
18. The segment accounted for 37.7% of the company's revenue in
FY2018.
• The segment reported 31.5% of its revenue from the US and 68.5% from
international markets in FY2018.
• In FY2018, Legacy Established products accounted for 52.1% of the EH
segment revenue, followed by sterile injectable pharmaceuticals for
25.8%; Peri-LOE Products for 14.6%; biosimilars for 3.8% and Pfizer
CentreOne for 3.7%.
• EH segment revenue in FY2018 decreased due to decline in
performance of legacy established products, sterile injectable
pharmaceuticals and peri-LOE products.
Innovative Health (IH) – Performance
IH segment reported revenue of US$33,426.0 million for FY2018, which
grew 6.4% YoY, and recorded a CAGR of 7.0% during 2016-18. The
segment accounted for 62.3% of the company's revenue in FY2018.
• The segment reported 56.7% of its revenue from the US and 43.3% from
international markets in FY2018.
• In FY2018, IH segment reported 29.9% of its revenue from internal
medicine; 21.6% from cancer; 18.9% from vaccines; 12.2% from
inflammation and immunology; 10.8% from consumer healthcare; and
6.6% from rare disease.
• Segment revenue growth in FY2018 was primarily driven by major
brands such as Eliquis, Ibrance, Prevnar 13/Prevenar 13 and Xeljanz
(globally).

4. 4
Company’s Financial Performance
Revenue by Segment and Geography
($billion of dollars)
Financial information as of FY Dec 2018
25.3 26 26.4
28.3 26.5 26.5
6.4 7.6 9.6
13.9 13.6 14
19.0 18.5 16.8
14.5 13 12.4
IH
2018
IH
2017
IH
2016
EH`
2018
EH
2017
EH
2016
Pfizer`
2018
Pfizer
2017
Pfizer
2016
U.S. International Total
$2.40
2016
$2.65
2017
$3.00
2018
An increased Diluted EPS
RETURNED OVER
$12.3bn
to shareholders through dividends
and share repurchases in 2016

5. 5
Strategic Imperatives
1
Innovate and Lead
Improve Pfizer's ability to innovate
in biomedical R&D and develop a
new generation of high value, highly
differentiated medicines and
vaccines
2
MAXIMIZE VALUE
Invest and allocate our resources in
ways that create the greatest long-
term returns for our shareholders
3
Earn Greater Respect
Earn society's respect by generating
breakthrough therapies, improving
access, expanding the dialogue on
health care and acting as a
responsible corporate citizen
4
Own Our Culture
Build and sustain a culture where colleagues
view themselves as owners, generating new
ideas, dealing with problems in a
straightforward way, investing in open and
candid conversations and working as
teammates on challenges and opportunities

6. 6
R&D Overview
R&D activities focus on providing innovative products in the areas of biosimilars, immune disorders and inflammation,
cardiovascular and metabolic diseases, cancer, neurological diseases, rare diseases and vaccines.
 In FY2018, the company spent US$8,006 million on R&D activities, which as a percentage of revenue stood at 14.92%.
 As of January 29, 2019, Pfizer had 100 Projects in clinical research and development including 54 NMEs, 41 additional
indications and five biosimilars.
 Its R&D platforms include Gene Therapy, Medical Sciences, Precision Medicine and Biosimilars.
 It has R&D collaborations with Cystic Fibrosis Foundation Therapeutics (CFFT), Centers for Therapeutic Innovation (CTI) and
National Center for Advancing Translational Sciences (NCATS).
 It has R&D facilities in Massachusetts, California, Missouri, Connecticut and New York in the US; and Cambridge and
Sandwich in the UK.
 Owns numerous US and foreign patents covering pharmaceutical and other products and their uses, product manufacturing
processes, pharmaceutical formulations and intermediate chemical compounds used in manufacturing.
Revenues by Operating Segment and Geography

7. 7
Business Development Initiatives
Invested Half Billion Dollars To Advance State-of-the-art Gene Therapy Facility In Sanford, North Carolina
• On August 21, 2019, acquired an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing
facility in Sanford, North Carolina
• This facility would expand the company’s presence in North Carolina, the expanded facility is projected to add approximately 300 new jobs
Completed Acquisition Of Array Biopharma
• On July 30, 2019, completed the acquisition of Array Biopharma
• Strengthens Pfizer’s innovative biopharmaceutical business and category leadership in Oncology Expected acceleration of Pfizer’s long-term
growth trajectory through new medicines, including the breakthrough combination of BRAFTOVI® and MEKTOVI®
Agreement To Form A New Consumer Healthcare Joint Venture (IH)
• On December 19, 2018, announced to enter into a definitive agreement with G`SK under which we and GSK agreed to combine our respective
consumer healthcare businesses into a new consumer healthcare joint venture that will operate globally under the GSK Consumer Healthcare
name
Sale of Hospira Infusion Systems Net Assets to ICU Medical, Inc. (EH)
• On February 3, 2017, completed the sale of our global infusion systems net assets, HIS, to ICU Medical
• In connection with this transaction, recognized pre-tax income of $1 million in 2018 and pre-tax losses of $55 million in 2017 in Other
(income)/deductions––net
Acquisition of AstraZeneca’s Small Molecule Anti-Infectives Business (EH)
• On December 22, 2016, acquired the development and commercialization rights to AstraZeneca’s small molecule anti-infectives business,
primarily outside the U.S. The total fair value of the consideration transferred for this business was approximately $1,040 million, inclusive of cash
paid and the fair value of contingent consideration

8. 8
Acquisition of Medivation, Inc. (IH)
• On September 28, 2016, acquired Medivation for $81.50 per share
• Medivation’s portfolio includes Xtandi (enzalutamide), an androgen receptor inhibitor that blocks multiple steps in the androgen receptor
signaling pathway within tumor cells, and talazoparib, approved by the FDA in October 2018, under the trade name Talzenna and others
Research and Development Arrangement with NovaQuest Co-Investment Fund II, L.P.
• On November 1, 2016, announced the discontinuation of the global clinical development program for bococizumab.
Acquisition of Bamboo Therapeutics, Inc. (IH)
• On August 1, 2016, acquired all the remaining equity in Bamboo, a privately-held biotechnology company focused on developing gene therapies
for the potential treatment of patients with certain rare diseases relating to neuromuscular conditions
Research and Development Arrangement with RPI Finance Trust
• In January 2016, Pfizer entered into an agreement with RPI, a subsidiary of Royalty Pharma, under which RPI would fund up to $300 million in
development costs related to certain Phase 3 clinical trials of Pfizer’s Ibrance (palbociclib) product primarily for adjuvant treatment of hormone
receptor positive early breast cancer (the Indication)
Business Development Initiatives

9. 9
Technological Efforts…
Initiating an enterprise-wide digital
effort to help speed up
drug development, enhance
patient and physician
experiences and access and
leverage technology and
robotics to simplify and
automate our processes
Advances in both biological
science and digital technology that
are enhancing the delivery
of breakthrough new
medicines; and the
increasingly significant role of
hospitals in healthcare systems
Work in close collaboration with its Global Product Development
organization (GPD), which has expertise in various
disciplines such as Biostatistics, Clinical
Pharmacology and Digital Medicine
GPD also helped to enable more efficient
and effective development and enhance Pfizer’s ability to
accelerate and progress assets through its pipeline
Strong focus across the grants on strengthening
local healthcare systems and building capacity,
including through primary healthcare delivery
and the integration of innovative health
technologies in low-resource settings
The Pfizer Foundation’s flagship GHIG program
(managed in partnership with Innovations in Healthcare
(IiH), a nonprofit organization hosted by Duke
University)
GHIG program combines grant investments with
technical support to help accelerate global health
innovations by giving partners the autonomy to navigate
the unique and fluid challenges they face in their local –
and often last mile – communities
Invested half billion dollars to advance
state-of-the-art gene therapy facility
in sanford, north carolina
Investment will further strengthen
Pfizer’s leadership in gene therapy
manufacturing technology and would increase
Sanford’s high-tech manufacturing environment

10. 1
0
Technological Efforts
Opened new state-of-the-art biologics clinical manufacturing facility in
andover, massachusetts
The new ACMF is a multiproduct manufacturing facility with a flexible design
that allows clinical products to be manufactured more efficiently and fully
enable next-generation manufacturing technologies
Ochsner Health System and Pfizer partnered to develop innovative models for
clinical trials
“Partnering with Pfizer allows us to transform medicine by creating a digital clinical
trial experience that improves patient participation, integration, communication
and accessibility.”
Alliance supports participating patients the opportunity to test of its new digital
tools designed to make the clinical trial experience more inclusive and enjoyable
Towards accelerating and
improving its digital
capabilities Pfizer recently
appointed Lidia Fonseca
(organization’s first digital
officer) who will be
responsible in creating and
implementing its strategy to
foster the business growth
and to compete with its rivals
to deliver more values to
patients
As a part of its digital transformation strategy, the
company modernized most of its 35 enterprise products,
migrating them to the cloud
By improving their efficiency, the company has been able
to reduce operating costs for both the IT department and
the whole organization by about $1.5 billion
Center of Excellence of analytics is an award-winning
initiative, using numerous pools of clinical data to create
more efficient medicine
In 2011, the company made a big bet on the Internet of
Things developing an experimental Parkinson’s treatment
By collaborating with the IBM Watson team, the company
was developing a sensor-enabled remote patient
monitoring system that would make it possible to track
patient health and activity in their day-to-day life outside
of the clinical trial labs

11. 1
1
Digital Initiatives
Pfizer, Concerto HealthAI join up for precision medicine partnership
• The partnership will use the AI platform to gain faster actionable insights for Pfizer‘s investigational therapies and
commercialized therapeutics for treatment of solid tumors and hematologic malignancies, officials said.
• Pfizer is working with Boston-based Concerto HealthAI for a collaboration that will apply Concerto's eurekaHealth artificial
intelligence technology to precision oncology research.
Pfizer eyes AI-powered drug discovery and development software
• Pfizer has partnered with a ‘computation-driven’ pharmaceutical technology company to develop a drug discovery platform
powered by artificial intelligence (AI). Its collaboration with Cambridge, Massachusetts-based XtalPi will see the firms work on
molecular modelling software that can be applied to drug-like small molecules.
• Charlotte Allerton, Pfizer’s head of medicine design, said: “The XtalPi collaboration is an opportunity to enhance our
computational modelling capabilities. “We are looking forward to potentially utilising new tools to increase our effectiveness in
small molecule drug discovery and development.”
Digitizing the supply chain: Why Pfizer is investing in IoT, drones and personalized medicine
• Within organization Pfizer is constantly looking at opportunities to further digitize the supply chain, in the scope of a journey
which started several years ago and marked already very important milestones. The ultimate goal is to create a highly
orchestrated supply network, which guarantees full end-to-end visibility, not just to its internal stakeholders, but also to its
patients. As you can imagine, this is particularly critical in an industry where a product must not only satisfy customer demand,
but also be capable at times of saving human lives.
Digitizing the supply chain: Why Pfizer is investing in IoT, drones and personalized medicine
• Within organization Pfizer is constantly looking at opportunities to further digitize the supply chain, in the scope of a journey
which started several years ago and marked already very important milestones. The ultimate goal is to create a highly
orchestrated supply network, which guarantees full end-to-end visibility, not just to its internal stakeholders, but also to its
patients. As you can imagine, this is particularly critical in an industry where a product must not only satisfy customer demand,
but also be capable at times of saving human lives.

12. 1
2
Digital Initiatives
Leading a Transformative Approach to Precision Medicine
• Working with IBM Health Watson fuels our immune-oncology research One of the major recent advances in the battle against
cancer has been immune-oncology, which uses the body’s immune system to fight the disease. The future of immune-oncology
may lie in combining therapies and tailoring them to unique tumor characteristics.
• Yet, the number of potential therapy combinations is almost impossible to quantify, let alone test. Therefore, one of the great
challenges in immune-oncology is to find ways to narrow the field of focus so we can more efficiently identify effective
combinations.
• To accelerate its work in this space, Pfizer is working with IBM Health Watson.
Pfizer, other pharmacy companies join block chain project
• According to Block chain News, to reduce costs, errors and inefficiencies, Pfizer and other pharmaceutical companies have
joined a block chain project led by technology company Chronicle.
• The MediLedger Project is an initiative that aims at building block chain-based ecosystems and supply chain solutions.
McKesson Corp., AmerisourceBergen Corp., and Premier are the other companies that will be part of the block chain project.
• The block chain network expects to go live in the second quarter of this year. In earlier testing, the request and response time
averaged to less than 400 milliseconds. MediLedger also established a protocol for saleable return drug verification that meets
the FDA's 2019 Drug Supply Chain Security Act regulations.
Pfizer And Others Join Working Group To Use Blockchain Protocol For Supply Chain Management
• Leading life sciences and healthcare companies Pfizer Inc., McKesson Corporation, AmerisourceBergen Corporation, and
Premier Inc. have all joined a working group that is using blockchain technology to dramatically improve the complex process
of chargeback's.
• “Chargeback's in healthcare are not a regulatory driven problem, but rather a business inefficiency. Last summer we came
together with a smaller set of companies to build a prototype to solve some of the problems that happen today between
contracting and chargeback's. We are excited to announce the addition of leading healthcare companies to the working group,”
Susanne Somerville, Chronicle's CEO, told me.”

13. “Big data” and analytics bring
new insights and huge
opportunity to drive
innovation
Data will help scientists to
more efficiently develop
medicines and better define
which patients will benefit
most from specific treatments
and vaccines
1
3
Strategy/Imperative
$200bn
Analytics can reduce health
care expenditures by $200
billion in the U.S. alone by the
end of the decade.
Pfizer uses data at all stages
of the research and
development process to help
discover potential medicines,
assess efficacy in clinical trials
and help ensure
manufacturing and supply
chain excellence
$7.7bn
In 2017 company
invested into researching
and developing new
treatments
At Pfizer, it does not only
collaborate with academia
and patient organizations to
share expertise in a common
area, but also work with other
companies to potentially
accelerate new innovations
and therapies
The company
uses data at all
stages of the
research and
development
process
to help discover
potential medicines,
assess efficacy in clinical
trials and help ensure
manufacturing and
supply chain excellence.
Leader in transforming the
way researchers approach
clinical trials. Company readily
embrace cutting-edge
technology, strategies and
partnerships to ensure our
high-quality clinical trials are
conducted with speed and
agility, and to maximize its
ability to bring innovative
medicines and vaccines to
patients as quickly as
technologies evolve
In the past five
years, we invested
$2.1 billion in U.S.
manufacturing
and our 15 U.S.
manufacturing sites,
employing more than
11,000 people, help
produce almost 60 percent
of our medicines.

14. 1
4
Manufacturing & Supply Chain Excellence
Purpose is to bring innovative medicines and
vaccines to patients and healthy individuals
In 2017, continued to strive to set the industry
standard for quality, safety and value in the
development and manufacturing of our
medicines
Under Pfizer Global Supply (PGS), company
harness data to inform our decisions and
processes, creating a highly efficient
manufacturing and supply network that
continually optimizes the way we deliver
medicines to our patients.
Continue to use operational and supply chain
data from enterprise systems to identify
processes to better meet the needs of patients
In 2017, this information helped company to
address drug shortages of several injectable
medicines used in hospitals and other clinical
settings
Pfizer and local political leaders joined Sanford,
North Carolina, colleagues to celebrate expansion
plans for the new state-of-the-art gene therapy
facility under construction. The event featured a
View Into the Future, including an exhibit and
virtual tour of the future manufacturing facility.

15. 15
Merger & Acquisitions
Announced
Date
Closed
Date
Transaction
Type
Role Target Buyer/Investors Sellers
Size
(US$
Million)
Jul-29-2019 - Merger/Acquisition Seller Upjohn Inc. Mylan N.V.
(NasdaqGS:MYL)
Pfizer Inc. -
Jun-17-2019 Jul-29-
2019
Merger/Acquisition Buyer Array BioPharma Inc. Pfizer Inc. (NYSE:PFE) 11,499.34
May-08-2019 Jul-01-
2019
Merger/Acquisition Buyer Therachon AG Pfizer Inc. (NYSE:PFE) 810.0
Mar-20-2019 Mar-20-
2019
Merger/Acquisition Buyer Vivet Therapeutics SAS Pfizer Inc. (NYSE:PFE) 51.1
Sep-25-2018 Sep-25-
2018
Merger/Acquisition Seller NextWave
Pharmaceuticals Inc
Tris Pharma, Inc. Pfizer Inc. -
Jul-13-2018 Jul-13-
2018
Merger/Acquisition Seller Office Buildings At 219 and
235 East 42nd Street in
Manhattan
Alexandria Real Estate
Equities, Inc.
(NYSE:ARE); David
Werner Real Estate
Investments; Deutsche
Bank AG, New York
Branch, Asset
Management Arm
Pfizer Inc.
(NYSE:PFE)
357.0
M&A’s activity of Pfizer in last two years.

16. 16
Merger & Acquisitions
Announced
Date
Closed
Date
Transaction
Type
Role Target
Buyer/Investor
s
Sellers
Size
(US$
Million)
Dec-26-2017 Feb-13-
2018
Merger/Acquisition Seller Sucampo
Pharmaceuticals,
Inc.
Mallinckrodt plc
(NYSE:MNK)
Alexandria Real Estate
Equities, Inc.; Bay City Capital
LLC; BlackRock Fund
Advisors; ING Groep NV,
Insurance and Banking
Investments; Lundbeckfond
Invest A/S; New Enterprise
Associates; Pfizer Inc.; S&R
Technology Holdings, LLC;
Sachiko Kuno Foundation,
Inc., Endowment Arm Seller
Funds:
1,220.64
Nov-10-2017 Nov-10-
2017
Merger/Acquisition Seller Hisun-Pfizer
Pharmaceuticals
Co., Ltd
Hillhouse Capital
Management, Ltd.
Pfizer Inc. 286.0
Aug-08-2017 Dec-31-
2017
Merger/Acquisition Seller Pfizer Inc., Sterile
Manufacturing
Facility in Liscate,
Italy
Avara Pharmaceutical
Services, Inc.
Pfizer Inc. -
Jul-11-2017 Aug-28-
2017
Merger/Acquisition Seller Protein Sciences
Corporation
Sanofi Pasteur Inc. Johnson & Johnson; Mertiva
AB (publ); Pfizer Inc.; Ropart
Asset Management Funds
750.0
Jul-04-2017 Aug-16-
2017
Merger/Acquisition Seller Laboratório
Teuto Brasileiro
S.A.
Pfizer Inc. -
May-04-2017 Apr-04-2017 Merger/Acquisition Seller Rives de Paris
located in the
'Zac Francois
Ory'
AXA Real Estate
Investment Managers
SGP; AXA
Selectiv´Immo
Pfizer Inc. -
M&A’s activity of Pfizer in last two years.